Recent Updates
Recently added Catalysts
REGN

regeneron announces investor conference presentations

Key Takeaway: regeneron announces investor conference presentations
Price reaction · baseline $750.57 (2026-04-17 close) · 2 other REGN headline(s) in the window, move may be shared
day 0 close · peak
-0.2%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
2.6%
average across 15 past catalysts
Lead asset
VEGF Trap-Eye
Phase 1 · Diabetic Macular Edema

Full Press Release Details

TARRYTOWN, N.Y., April 20, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) will webcast management participation as follows:
• BofA Securities Health Care Conference 2026 at 10:00 a.m. PT (1:00 p.m. ET) on Tuesday, May 12, 2026
• Goldman Sachs 47thAnnual Global Healthcare Conference at 2:00 p.m. ET on Monday,  June 8, 2026
The sessions may be accessed from the "Investors & Media" page of Regeneron's website athttps://investor.regeneron.com/events-and-presentations. Replays and transcripts of the webcasts will be archived on the Company's website for at least 30 days.
About RegeneronRegeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to numerous approved treatments and product candidates in development, most of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.
Regeneron pushes the boundaries of scientific discovery and accelerates drug development using our proprietary technologies, such asVelociSuite®, which produces optimized fully human antibodies and new classes of bispecific antibodies. We are shaping the next frontierof medicine with data-powered insights from the Regeneron Genetics Center®and pioneering genetic medicine platforms, enabling us to identify innovative targets and complementary approaches to potentially treat or cure diseases.
For more information, please visitwww.Regeneron.comor follow Regeneron onLinkedIn,Instagram,FacebookorX.

Contact Information:Investor RelationsRyan Crowe914.847.8790ryan.crowe@regeneron.com

Last updated: Apr 20, 2026